GlassScriptPhysician profile
Pranav B Sheth
NPI 1518904838
$978,287.06
in general payments reported to CMS, 2019-2025
30 companies · $136K in 2025
The $136K reported for 2025 was more than what 98% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190K · 2020: $76K · 2021: $86K · 2022: $103K · 2023: $185K · 2024: $203K · 2025: $136K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $392K · Travel and Lodging: $65K · Honoraria: $31K · Consulting Fee: $19K · Food and Beverage: $16K · Education: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $391,760.00 |
| Travel and Lodging | $65,270.95 |
| Honoraria | $31,200.00 |
| Consulting Fee | $19,460.00 |
| Food and Beverage | $15,571.63 |
| Education | $347.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $526,136.93 | 2019-2025 | Rinvoq, Skyrizi |
| Dermavant Sciences, INC. | $165,167.87 | 2022-2024 | Vtama |
| Lilly USA, LLC | $148,644.65 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $83,785.71 | 2019-2025 | Cosentyx |
| Organon LLC | $37,941.15 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $6,716.62 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $1,909.36 | 2021-2022 | |
| Ucb, INC. | $1,896.03 | 2020-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $1,767.21 | 2020-2025 | Anzupgo |
| Regeneron Healthcare Solutions, INC. | $1,130.50 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $545.81 | 2020-2025 | Ilumya |
| Janssen Scientific Affairs, LLC | $425.46 | 2019-2025 | Tremfya |
| Incyte Corporation | $379.30 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $355.10 | 2020-2025 | Tremfya, Simponi, Simponi Aria |
| Arcutis Biotherapeutics, INC. | $244.68 | 2023-2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $207.55 | 2019-2020 | |
| Galderma Laboratories, L.P. | $193.41 | 2021-2025 | Nemluvio |
| Regeneron Pharmaceuticals, INC. | $191.73 | 2023-2025 | Dupixent |
| Amgen INC. | $172.38 | 2019-2025 | Otezla |
| Kyowa Kirin, INC. | $101.56 | 2024-2025 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.25 | 2022-2025 | Spevigo |
| Vyne Pharmaceuticals INC. | $55.75 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $55.67 | 2025 | Acthar |
| Celgene Corporation | $41.21 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $31.36 | 2019-2022 | |
| Almirall LLC | $24.14 | 2021-2022 | |
| Biofrontera INC. | $19.35 | 2025 | Ameluz |
| Krystal Biotech INC | $18.79 | 2025 | Vyjuvek |
| Botanix Sb INC | $17.90 | 2025 | Sofdra |
| Pfizer INC. | $17.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pranav Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.